About - ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.

Zylox-Tonbridge Medical

Innovation for Quality Life

Zylox-Tonbridge Medical is an innovative medical technology company focused on peripheral and neurovascular intervention. Since our establishment in 2012, we have built an integrated platform covering R&D, manufacturing, regulatory registration and commercialization, supported by specialized technology platforms and strong operational capabilities.

Guided by our philosophy of "Innovation for Quality Life," we address real-world clinical needs through differentiated technologies and high-quality vascular intervention solutions. Our portfolio spans both commercialized and pipeline products, serving physicians and patients in China and international markets.

With expanding global presence and long-term clinical collaboration, Zylox-Tonbridge continues to advance vascular care through innovation, quality and responsibility, striving to become a trusted global partner in vascular intervention.

Our Values

Core Values

Integrity

Responsibility

Excellence

Cooperation

Mission and Vision

We are dedicated to building a comprehensive treatment platform for vascular diseases, providing high-quality and affordable medical products for all patients. Regardless of race, age, or wealth, every patient can benefit from the well-being and health brought by Zylox-Tonbridge.

Corporate Milestones

Commercial network covering 83 countries and regions worldwide
Tonbridge Medical Innovation Base put into operation
Zylox-Tonbridge approved for additional B share issuance
Over 1,000,000 units of our products have been used in clinical procedures

2025

Achieved full-year profitability for the first time
Dr. Jonathon Zhong Zhao included in the inaugural list of Zhejiang Province Science and Technology Entrepreneurs
Zylox-Tonbridge entered into a strategic collaboration with Avinger, Inc.

2024

Selected as a National-level "Little Giant" Specialized and Sophisticated Enterprise
Establishment of Zylox-Tonbridge Public Charity Special Fund
Multiple core products seized volume-based procurement opportunities, achieving rapid market access and share growth

2023

Groundbreaking of Tonbridge Medical Innovation Base
Establishment of subsidiaries in the Netherlands and Singapore to accelerate internationalization
Global headcount exceeded 700

2022

Grand opening of Zylox-Tonbridge Industrial Park
Successful listing of the Company on the Stock Exchange of Hong Kong
Establishment of offices and R&D centers in Beijing and Shanghai

2021

Company enters full commercialization phase
Four products, including UltraFree® DCB and Thrombite™ Clot Retriever Device, approved by NMPA for market launch

2020

Completion of Series B and B+ Financing
Groundbreaking of Zylox-Tonbridge Industrial Park
Completion of clinical trials for UltraFree® DCB and Thrombite™ Clot Retriever Device

2019

2nd Prize (Growth Group) at the 7th China Innovation and Entrepreneurship Competition (Biomedicine Sector)
ZenFlow™ PTA Balloon Catheter approved by NMPA for market launch

2018

2nd Prize (Growth Group) at the 6th China Innovation and Entrepreneurship Competition (Biomedicine Sector)
Thrombite™ Clot Retriever Device designated as Innovative Medical Device by NMPA

2017

Tonbridge Medical established, entering the neurovascular intervention field
UltraFree® DCB designated as Innovative Medical Device by NMPA

2016

Completion of Series A Financing
First CE certification obtained for products

2015

Recognized as "Provincial Key Enterprise Research Institute for Vascular Medical Devices"

2014

Founding of Zhejiang Zylox Medical Devices Co., Ltd. (predecessor of the Company)
Zylox Medical established

2012

Explore More

Leadership

Founder, Chairman

Dr. Jonathon Zhong Zhao

Chairman and Chief Executive Officer

Management Team

Mr. Xie Yang

Executive Director and Senior Vice President

Dr. Li Zheng

Executive Director and Senior Vice President

Mr. Yuan Quanwei

Chief Financial Officer

Asia

Kazakhstan

Indonesia

Thailand

Malaysia

Saudi Arabia

United Arab Emirates (UAE)

Iran

Azerbaijan

South America

Argentina

Ecuador

Brazil

Africa

South Africa

Europe

Germany

France

Italy

U.K.

Turkey

Poland

Belarus

Ukraine



Germany

Global R&D and Operations Center,
Optimed Headquarters

Global Presence

Zylox-Tonbridge is expanding its global presence across Europe, Latin America, the Middle East, Africa and Asia-Pacific, with products commercialized in more than 80 countries and regions worldwide.

Driven by its peripheral and neurovascular intervention businesses, the Group is advancing access to innovative vascular solutions through international commercialization, localized operations and long-term clinical collaboration.

Supported by its global operations and R&D center in Germany, Zylox-Tonbridge has established international commercial, warehousing and logistics capabilities, enabling stronger local market responsiveness, clinical engagement and cross-border collaboration.

To date, the Group's products have been used in more than 1.1 million clinical procedures globally, supporting physicians worldwide in delivering high-quality vascular care.

ESG at Zylox-Tonbridge

Guided by "Innovation for Quality Life," we embed ESG into our business to advance patient care, uphold responsible operations, and create long-term value for stakeholders.

Explore More

News from Zylox-Tonbridge

Stay informed with the latest company news from Zylox-Tonbridge.